Valneva to Present at Upcoming Healthcare Investor Conferences

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has announced that its senior management will participate in upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach will present at the TD Cowen 44th Annual Health Care Conference, taking place March 4 – 6, 2024, in Boston, MA. Mr. Lingelbach and CFO Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen Life Sciences Conference, held April 16 – 17, 2024, in Amsterdam, The Netherlands.

At these conferences, Valneva's management will discuss the company's growing commercial business and pipeline of infectious disease vaccines. IXCHIQ®, Valneva's third commercial product and the world's first approved vaccine against chikungunya virus, was recently recommended for use by the U.S. CDC Advisory Committee on Immunization Practices (ACIP) and is expected to launch in 2024. The single-shot vaccine is also under regulatory review in Canada and Europe and was granted accelerated assessment by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP). A decision for both submissions is expected mid-2024.

VLA15, the Company's Lyme disease vaccine candidate, is currently in Phase 3 clinical development and partnered with Pfizer for this study and global commercialization. Recruitment completion for the study was announced in December 2023. Valneva's strong track record in advancing multiple vaccines from early R&D to approvals, and its current commercialization of three proprietary travel vaccines, including the world's first chikungunya vaccine, have contributed to its growing commercial business and the advancement of its vaccine pipeline.

Valneva's strategy of focusing on first-, best-, or only-in-class vaccine solutions positions it as a specialized and targeted player in the competitive landscape of the vaccine market. By applying its deep expertise across multiple vaccine modalities, Valneva aims to provide innovative and effective vaccine solutions for unmet medical needs. This approach is evident in its pipeline of potential first-in-class vaccine candidates, such as its lead Lyme disease vaccine, VLA15, and its Shigella and Zika programs, alongside its portfolio of marketed vaccines.

In conclusion, Valneva's participation in upcoming investor conferences, along with its growing commercial business and pipeline of infectious disease vaccines, demonstrates the company's commitment to advancing its vaccine portfolio and addressing unmet medical needs in the global vaccine market.